New patient studies surrounding the medication Retatrutide , specifically the 120mg formulation ZPHC ZPHC, indicate a considerable benefit on weight reduction and linked chronic illnesses . Researchers anticipate that this dual acting , targeting both GLP-1 and GIP pathways , has the potential to offer a substantial improvement in the treatment of